Aterian Inc vs Zimmer Biomet Holdings Inc — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while Zimmer Biomet Holdings Inc trades at $95.71 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3486.8× Aterian Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | ZBH | |
|---|---|---|
Market Cap | $5.32M | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $107.71 |
52-Week Low | $0.36 | $79.58 |
Enterprise Value | $5.90M | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.48, down 2.72% on the day, with a bearish technical signal. The company reported a net loss of -$18.98M in 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights a pending asset sale that could return $0.85–$1.14 per share to stockholders, subject to a special meeting vote.
The outlook hinges on the asset sale approval, offering potential upside, but ongoing operational losses and negative cash flow pose significant risks. Analyst sentiment is split evenly between Buy and Hold, reflecting uncertainty around the company's restructuring and future profitability.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →